Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas Bacteremia

NCT06113107 | Unknown

• 1 other identifier: 8786
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

Modification of the rendering of the antibiogram at the Strasbourg University Hospital in November 2019 with the appearance of the concept of "standard dose" or "high dose" sensitivity. This modification seems to have favored an inappropriate overprescription of Meropenem (the only antibiotic made "at standard dose") in Pseudomonas infections sensitive to other beta-lactams. In June 2021, it was therefore decided to mask sensitivity to carbapenems by default in the rendering of Pseudomonas antibiograms when the strain was sensitive to a narrower spectrum beta-lactam ("restricted" antibiogram). The aim of this study is to evaluate the impact of these changes in the antibiogram on antibiotic prescriptions.

Conditions

Pseudomonas

Keywords

Pseudomonas; Meropenem; Microbial susceptibility testing; EUCAST breakpoint; Antibiotic stewardship

Outcome Measures

Primary Outcomes (1)

• Proportion of Meropenem prescriptions in Pseudomonas spp bacteraemia susceptible to narrow-spectrum betalactams

  This study is retrospective, the analysis focuses on the medical records of patients treated at the Strasbourg University Hospital between June 1, 2018 and November 30, 2022.

  Files analysed retrospectively from June 1, 2018 to November 30, 2022 will be examined

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Major subject (≥18 years old) with a positive blood culture result for Pseudomonas spp identified in the microbiology laboratory of Strasbourg University Hospital during the period from June 1, 2018 to November 30, 2022

You may qualify if:

• Major subject (≥18 years old)
• Subject with a positive blood culture result for Pseudomonas spp identified in the microbiology laboratory of Strasbourg University Hospital during the period from June 1, 2018 to November 30, 2022
• Subject not opposing the reuse of their data for the purposes of this research.

You may not qualify if:

• Subject having expressed opposition to participating in the study,
• Pseudomonas spp strain resistant to all first-line beta-lactams (Piperacillin-Tazobactam, Ceftazidime, Céfepime and Aztreonam).
• Pseudomonas spp strain resistant to Meropenem.
• Lack of information on the antibiotic treatment undertaken.

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Pseudomonas Infections

Condition Hierarchy (Ancestors)

Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections

Central Study Contacts

Yvon RUCH, MD

CONTACT

33 3 69 55 12 19; yvon.ruch@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 24, 2023
• First Posted: November 2, 2023
• Study Start: March 1, 2023
• Primary Completion: March 1, 2024
• Study Completion: March 13, 2024
• Last Updated: November 2, 2023

Record last verified: 2023-10

Locations

FR (1)